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COMMENTARY

What’s Wrong with This Picture?
A Critical Review of Current Centers
for Medicare & Medicaid Services Coverage Criteria
for Continuous Glucose Monitoring
Rodolfo J. Galindo, MD, FACE,1–3,* Christopher G. Parkin, MS,4,{ Grazia Aleppo, MD, FACE, FACP,5
Anders L. Carlson, MD,6–9 Davida F. Kruger, MSN, APRN-BC, BC-ADM,10 Carol J. Levy, MD, CDE,11,12
Guillermo E. Umpierrez, MD,13,14 and Janet B. McGill, MD, MA, FACE, FACP15,{

Abstract

Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1
diabetes and type 2 diabetes populations. However, the eligibility criteria for CGM coverage required by the
Centers for Medicare & Medicaid Services (CMS) ignore conclusive evidence that supports CGM use in various diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the CMS eligibility criteria relative to current scientific evidence and proposes workable
solutions to address this issue and improve the safety and care of all individuals with diabetes.
Keywords: Continuous glucose monitoring, Centers for Medicare & Medicaid Services, Insurance coverage,
Type 1 diabetes, Type 2 diabetes.
The increasing prevalence in the United States continues
to be a significant and growing health issue. However, the
concern is greatest among racial and ethnic minority populations, in which the prevalence of diabetes and its debilitating complications is significantly higher than the broader
white population.5 According to the latest estimates, the prevalence of diagnosed diabetes is highest within the Native

Introduction

mong individuals ‡65 years, the prevalence of diabetes has now reached over 30%.1–4 In the recent Centers for Disease Control & Prevention 2020 report, it was
found that an additional 7.3 million adults who met laboratory criteria for diabetes were not aware of their condition.1
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American (14.7%), Hispanic American (12.5%), and nonHispanic black American (11.7%) populations compared
with non-Hispanic white (7.5%) populations.1,5
These disparities are most notable among the Medicare
diabetes population. Key findings from a 2017 report from
Centers for Medicare & Medicaid Services (CMS) revealed
that diabetes prevalence was higher among non-Hispanic
black (30.0%) and Hispanic beneficiaries (26.7%) compared
with non-Hispanic white beneficiaries (18.0%), but that significantly lower percentages of black (65.2%) and Hispanic
(64.3%) than white (79.4%) beneficiaries are aware that
Medicare helps pay for diabetes testing supplies and education.6 A 2018 survey by the Kaiser Family Foundation reported that the prevalence of diabetes was notably higher
within non-Hispanic black and Hispanic Medicare populations
compared with the non-Hispanic white population (Fig. 1).3
It is important to note that these statistics are from
government agency reports, which include comprehensive
descriptions of the various scientific methodologies used to
generate the data. However, there appears to be disconnection between how science is used to assess a problem but not
utilized in solving problems.
Although the medical community traditionally relies
on high-quality scientific evidence when developing clinical
guidelines for managing diabetes and other conditions, many
regulatory agencies and public and private insurers tend to
ignore the evidence and take a different path when establishing coverage eligibility criteria for medications and
medical devices. This is particularly apparent in the current
eligibility criteria for use of personal continuous glucose
monitoring (CGM), which deny millions of Americans access to this proven technology.
This article discusses the limitations and inconsistencies
of the CMS eligibility criteria relative to current scientific
evidence and proposes workable solutions to address this
issue and improve the safety and care of all individuals with
diabetes.
Evidence Supporting CGM Use in Various
Diabetes Populations
Type 1 diabetes

The clinical efficacy of CGM has been demonstrated for
over a decade in numerous studies of individuals with type 1
diabetes (T1D) regardless of insulin delivery method.7–23
Benefits of CGM use in this population include reductions in HbA1c,7,9,11,17,18,24–28 fewer severe hypoglycemia

FIG. 1.

events,25,26,29 increased time within target glucose range
(TIR),11,18,19,30 and reductions in time below range.11,18
Large observational registry and database studies have also
shown an association between CGM use and significant reductions in hospitalizations for severe hypoglycemia and
diabetic ketoacidosis (DKA)25,26,29,31 For example, in the
RESCUE trial, a multicenter prospective observational cohort study of T1D adults (n = 515) treated with insulin pump
therapy, switching from self-monitoring of blood glucose
(SMBG) to CGM during the 12-month observation period,
was associated with significant reductions in the number of
patients hospitalized for severe hypoglycemia, a decrease of
73% (from 11.9% to 3.2%),29 as well as DKA-related hospitalizations decreased by 80% (from 4.6% to 1.1%).
Problematic hypoglycemia regardless
of treatment regimen

Problematic hypoglycemia has been well-documented in
individuals with T1D and type 2 diabetes (T2D) who are
treated with intensive insulin therapy, and recent studies have
also reported problematic hypoglycemia in T2D patients
who are treated with less intensive insulin regimens or
no insulin.32–34 This is particularly concerning among older
patients, who are at significantly higher risk for severe hypoglycemia compared with younger patients due to their
age, diabetes duration, insulin therapy duration, glucose
variability, and higher prevalence of impaired hypoglycemia awareness.35–40 Early and recent studies, utilizing CGM
documentation, have demonstrated an increased risk of severe hypoglycemia among patients ‡65 years treated with
less intensive insulin regimens or oral antidiabetic medications.16,41,42 Importantly, as reported by Weinstock et al., the
risk of severe hypoglycemia is not associated with HbA1c
or mean glucose measured by SMBG.35 Recent studies
have shown that use of CGM compared with SMBG significantly reduces glycemic variability,17 a risk factor for severe
hypoglycemia,43–45 and the time spent in hypoglycemia21,22
among T2D adults treated with intensive insulin therapy.
In a recent study by Pratley et al., 203 older adults
(‡60 years) were randomized to CGM or SMBG use.46 At
6 months, CGM use was associated with decreases in severe
hypoglycemia compared with SMBG, showing significant
reductions in severe hypoglycemia incidence rates (per 100
person-years) compared with SMBG (1.9 vs. 22.4, respectively, P = 0.02). CGM use was also associated with reductions in the percentage of time spent <70 mg/dL (from 5.1%

Diabetes prevalence within the Medicare population by race/ethnicity.3
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to 2.7%) versus increases with SMBG use (from 4.7% to
4.9%), P < 0.001. Considering that the average cost for a
hypoglycemia-related hospitalization among Medicare beneficiaries is estimated at >$10,000,47 the 10-fold decrease
in severe hypoglycemia incidence rates reported by Pratley is
notable. It is therefore reasonable to suggest that CGM use
would significantly reduce health care costs while improving
the safety of T2D patients treated with less intensive insulin
regimens, particularly in older patients with frequent severe
hypoglycemia or impaired hypoglycemia awareness.
Apart from the acute clinical outcomes resulting from
severe hypoglycemia events, these episodes also impact
patients’ willingness to adhere to their prescribed therapy,
which can result in suboptimal glycemic control and increased risk of long-term complications.48,49 An international survey of 27,585 diabetes patients found that 25.8% to
46.7% of people with T2D reduced their insulin dosages
in response to hypoglycemia.50 CGM use has been shown to
reduce hypoglycemia fear and increase patient confidence
in avoiding/treating hypoglycemia.7,48 This is particularly
relevant in patients with problematic hypoglycemia.
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A 2020 systematic review and meta-analysis of remote monitoring and telehealth technologies in patients with diabetes
reported significant reductions in HbA1c levels.57 Importantly, a subgroup analysis showed that remote patient monitoring is effective for patients who are residents of cities,
especially when using monitoring software (e.g., Dexcom
Clarity, Abbott LibreView, Medtronic CareLink) as a component of the intervention.
Use of digital diabetes technologies that transmit and present CGM data in a standardized report, such as the Ambulatory Glucose Profile (AGP), support analysis of patient
glucose data to inform treatment decisions. When shared
with the patient, the AGP results were found to be an effective basis for education, helping achieve better understanding of glycemic variability and increasing involvement in
diabetes self-management.64 Most recently, use of remotely
monitored CGM data as a component of a comprehensive
telemedicine program showed statistically significant HbA1c
reductions (P < 0.001) in a cohort to 594 T2D adults treated
with less intensive insulin therapy or noninsulin medications.15
Current CMS Eligibility Criteria for CGM Coverage

Pregnancy

The CONCEPTT trial assessed the clinical impact of
CGM use versus SMBG within a cohort of 325 women with
T1D who were pregnant (£13 weeks gestation) or planning
to become pregnant.51 Significant increases in time in target
range with CGM compared with SMBG use (68% vs. 61%;
P = 0 $ 0034, respectively) were observed. CGM users also
experienced improved fetal outcomes, including lower incidence of large for gestational age (P = 0.0210), fewer neonatal
intensive care admissions lasting more than 24 h (P = 0.0157),
fewer incidences of neonatal hypoglycemia (P = 0 $ 0250),
and shorter length of hospital stay (P = 0 $ 0091).
Chronic kidney disease

Although few studies of CGM use in patients with advanced chronic kidney disease (CKD) have been conducted,
Joubert et al. demonstrated a strong association between iterative CGM and frequent treatment changes and improved
glycemic control without increased risk of hypoglycemia in
diabetes patients on chronic dialysis.52 The value of CGM
has also been shown in monitoring and managing glycemic
levels in nondiabetic patients with end-stage renal disease
who are undergoing dialysis.53 A recent analysis of the T1D
Exchange registry data set found that fewer participants using
CGM experienced an adverse renal outcome compared with
those with no history of CGM use.54 An added benefit of
CGM use in this population is that it provides additional data
regarding glycemic status via the Glucose Management Indicator, which is a more reliable method of monitoring longterm glycemic control compared to HbA1c.55
Telemedicine

Numerous meta-analyses and systematic reviews of randomized controlled trials have demonstrated that the addition
of telemedicine and telemonitoring interventions in patients
with T1D and T2D results in reductions in HbA1c,56–61 incidence of severe hypoglycemic events,60 diabetes-related
distress,62 and improvements in medication adherence.63

On January 12, 2017, CMS initiated coverage for use of
CGM among insulin-treated diabetes beneficiaries who met
the following eligibility criteria: (1) diagnosis of diabetes;
(2) documentation of frequent SMBG (defined as testing
‡4 times daily); (3) treatment with intensive insulin therapy
(defined as ‡3 insulin injections per day or use of a Medicarecovered insulin pump); (4) frequent adjustment of insulin
dosages based on blood glucose measurements; (5) face-toface consultation with clinician before initiating CGM;
and (6) follow-up face-to-face clinical consultations every
6 months. However, despite the demonstrated clinical benefits of CGM, many Medicare beneficiaries with diagnosed
diabetes do not meet these eligibility criteria and are thus
denied access to CGM technology.65 Most clinicians who
care for persons with diabetes are unfamiliar with the criteria
and documentation required to obtain a CGM for eligible
patients, further limiting use by patients treated in primary
care and clinic settings.
Recommended Changes to Current
Eligibility Criteria
Eliminate SMBG frequency requirement

Requiring SMBG frequency of ‡4 times daily is not
only overly restrictive but also medically unfounded and
should not be included in Medicare coverage criteria. In
the Ruedy study, 52% of the CGM users reported SMBG
frequency of <4 tests per day at baseline, with no association between HbA1c reductions and baseline SMBG
frequency.17 A similar absence of association between previous SMBG frequency and positive clinical outcomes with
CGM use has been observed in other large, randomized
trials.10,21,31
In the DIAMOND T2D study, the mean self-reported
SMBG frequency for the CGM and SMBG groups was 3.3
and 3.2, respectively, at baseline.10 At 6 months, the mean
change in HbA1c was significantly greater in the CGM group
(-1.0) compared with SMBG users (-0.6%), P = 0.005. No
association between baseline SMBG frequency and CGM
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outcomes was observed. Similarly, post hoc analysis of data
from the REPLACE study showed no association between
prior SMBG frequency (<4 · vs. ‡4 · daily) and outcomes.21
Findings from a recent retrospective claims that data analyses have also shown no association between prior SMBG
frequency and reductions in acute diabetes events (ADE)
associated with CGM use.31 In the analysis, a cohort of
12,521 individuals with T1D and T2D experienced reductions in ADE from 0.245 to 0.132 events/patient-year
(P < 0.001), with similar reductions observed in patients
testing <4 and ‡4 times per day.31 Importantly, many Medicare beneficiaries are unable to meet the ‡4 times per day
fingerstick testing requirement due to limited dexterity or
restrictions on the number of strips allowed by Medicare.66
Although ‡4 times per day fingerstick testing is required
for coverage, Medicare only covers 100 test strips per month
(*3 strips/day) unless clinicians are willing to provide additional documentation supporting more frequent testing.
Eliminate intensive insulin regimen requirements
for T2D

Studies have demonstrated that use of CGM by T2D patients confers significant reductions in HbA1c levels,10,13–15,17,
24,67,68
significant increases in percent time in range (defined
as glucose values between 70 and 180 mg/dL, %TIR),10,17
significant decreases in percent time below range (defined as
glucose values <70 mg/dL, %TBR),21,22 and significant reductions in diabetes-related hospitalizations31,69 regardless
of insulin regimen. Although a substantial number of T2D
Medicare beneficiaries are treated with less-intensive insulin
regimens, they are at much higher risk for severe hypoglycemia than younger patients.16,35,36,42
Eliminate requirement for frequent insulin dosage
adjustments based on glucose values

The requirement for a documented history of frequent insulin dosage adjustment based on SMBG values is unrealistic
and burdensome for both health care providers and patients,
and there is no evidence demonstrating its value as a predictor
of successful CGM use. Moreover, this requirement ignores
the safety features of CGM, which include the automated
alarms and alerts that warn patients of current or impending
hypoglycemia/hyperglycemia, enabling them to take immediate remedial action. Importantly, several instances of
U-500- and premixed insulin-related errors have been reported, resulting in severe hypoglycemia.70 These insulin
preparations are generally administered only once or twice
daily, which means that patients using these medications
are not currently eligible for CGM use, denying them an
important safety device. Finally, the specific wording of the
requirement for ‘‘injecting’’ insulin fails to address other
options for insulin administration (e.g., insulin infusion using
a pump and inhaled insulin).
Include telemedicine as an option
for clinical consultations

Apart from the fact that FDA labeling for current CGM
systems does not require in-person training, numerous studies have shown that use of telemedicine consults confers
significant glycemic56–61 and psychosocial62,63 benefits.
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Moreover, the successful utilization of telemedicine consults
during the COVID-19 pandemic71–75 highlights the clinical
value and utility of this approach to health care delivery. It is
hoped that this temporary allowance by CMS will continue
after the pandemic ends, and that Congress will include all
patients who choose this option, not just those in rural communities. Because many older patients may not have access
or unable to use more advanced telemedicine technologies,
remote consultations via telephone must be an option for
meeting the 6-month consult requirement for verifying continued CGM use.
Streamlined and standardized documentation
requirements for obtaining coverage

Because obtaining CMS coverage for CGM places an
unwarranted burden on clinicians and office staff who must
gather and submit substantial documentation,76 many clinicians are unwilling or unable to meet the documentation requirements. This, in turn, can be detrimental to patient care.
In a 2017 survey by the American Medical Association, 92%
of the 1000 physicians surveyed reported that prior authorizations delay patient treatment and negatively impact clinical
outcomes.77 Importantly, 78% of respondents reported that
the documentation requirements associated with obtaining
preauthorizations sometimes (57%), often (19%), or always
(2%) result in their patients discontinuing their prescribed
therapy. This is evidenced by the apparent racial/ethnic
disparities relative to CGM eligibility within the Medicare
population. A recent analysis of 2018 Medicare data found
that the majority (69%) of insulin-treated beneficiaries do not
qualify for CGM coverage under the current ‡4x daily blood
glucose testing requirement.65 However, the percentage of
ineligible non-Hispanic black (‡74%) and Hispanic (‡75%)
beneficiaries is notably higher than observed in non-Hispanic
white (68%) beneficiaries.
Provide clear guidance to Durable Medical
Equipment suppliers

Beneficiary access to CGM is further hindered by CMSs
lack of clarity in providing guidance to Durable Medical
Equipment (DME) suppliers for determining the medical
necessity for CGM in many of the coverage claims they receive. As a result, claims are often rejected by suppliers to
avoid potential financial penalties that could be imposed
by CMS.
Proposed Eligibility Criteria for CGM Coverage

To expand access to all individuals who would benefit
from CGM, streamline clinician documentation requirements
and clarify DME supplier guidance, the panel recommends
that CMS modify its eligibility requirements to include all
Medicare beneficiaries who meet any one of the first four
criteria below, and who also meet the fifth criterion:
1. Diagnosed with T1D.
2. Diagnosed with T2D and treated with any insulin
regimen.
3. Diagnosed with T2D and documented problematic
hypoglycemia regardless of diabetes therapy. This
would include a history of at least one of the following
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Table 1. Proposed Eligibility Criteria and Supporting Evidence
Criterion
1. Diagnosed with T1D.

2. Diagnosed with T2D and
treated with any insulin
therapy.
3. Diagnosed with T2D and
documented problematic
hypoglycemia regardless of
diabetes therapy. This would
include a history of at least
one of the following
conditions:
Level 2 (moderate)
hypoglycemia, characterized
by glucose levels £54 mg/dL.
Level 3 (severe)
hypoglycemia—characterized
by physical/mental
dysfunction requiring thirdparty assistance.
Nocturnal hypoglycemia.
4. CKD.

5. In-person or telemedicine
consultation with the
prescribing health care
provider before CGM
initiation and every 6 months
thereafter while continuing
CGM therapy.

Supporting evidence
CGM use confers:
Significant reductions in HbA1c.7,9,11,17,18,24–28
Significant reductions in severe hypoglycemia events.25,26,29
Significant increases in %TIR.11,18,19,30
Significant decreases in %TBR.11,18
Significant reductions in diabetes-related hospitalizations.25,26,29,31
Significant improvements in treatment satisfaction with less diabetes distress25,27,78
CGM use confers:
Significant reductions in HbA1c.10,13–15,17,24,67,68,79
Significant increases in %TIR.10,17
Significant decreases in %TBR.21,22
Significant reductions in diabetes-related hospitalizations.31,69
Older diabetes patients are at increased hypoglycemia risk:
T2D patients treated with antihyperglycemic medications (e.g., insulin,
sulfonylureas) are at higher risk for hypoglycemia than those treated with
nonhypoglycemia medications (e.g., metformin).16
T2D patients ‡65 years treated with basal insulin (typically one injection per day)
are at increased risk for severe hypoglycemia.42
A key driver of hypoglycemia risk is impaired hypoglycemia awareness.35,70
CGM use confers:
Significant reductions in diabetes-related hospitalizations, including severe
hypoglycemia events.31,69
Significant reductions in hypoglycemia fear and increases patient confidence in
avoiding/treating hypoglycemia,7,80 thereby supporting treatment adherence.48,49

CGM use facilitates:
More frequent treatment changes and improved glycemic control without increased
risk of hypoglycemia.52
Effective monitoring and managing glycemic levels in non-diabetic patients with
ESRD undergoing dialysis.53
Use of telemedicine consults:
Significantly reduces HbA1c.56–61
Reduces the incidence of severe hypoglycemic events.60
Significantly reduces diabetes-related distress.62
Significantly improves medication adherence.63
Effectively addresses the obstacles caused by the COVID-19 pandemic.71–75
Are more effective for patients who are residents of cities and using the websites as
their intervention method.57
Use of downloaded CGM data into standardized reports:
Supports patient education.64
Enhances patient engagement in their self-management.64

%TIR = percentage of time in glucose range (70–180 mg/dL); %TBR = percentage of time below target ranges (<70 mg/dL, <54 mg/dL).
CGM, continuous glucose monitoring; CKD, chronic kidney disease; ESRD, end-stage renal disease; T1D, type 1 diabetes; T2D, type 2 diabetes.

conditions: Level 2 (moderate) hypoglycemia, characterized by glucose levels £54 mg/dL; Level 3 (severe) hypoglycemia, characterized by physical/mental
dysfunction requiring third-party assistance; or nocturnal hypoglycemia
4. Advanced CKD at risk for hypoglycemia.
5. In-person or telemedicine consultation with the prescribing health care provider before CGM initiation
and every 6 months thereafter while continuing CGM
therapy. (Coverage for telemedicine consults should
be available for all patients regardless of geographic
location.)
Table 1 presents the link between these proposed criteria
and their supporting evidence.

Conclusion

A substantial and growing body of evidence clearly demonstrates the clinical benefits of CGM in individuals with
T1D and T2D regardless of their current therapy and prior
glucose monitoring frequency.21,31,67–69,79,81,82 The medically unfounded Medicare eligibility criteria for CGM coverage and lack of clear guidance to DME suppliers deny
access to CGM among a substantial population of Medicare
beneficiaries with diagnosed diabetes. To the extent that
Medicare’s coverage criteria are adopted by Medicaid or
commercial payers, these policies have a negative ripple
effect on access to CGM.
Restricted access to CGM is particularly concerning within
populations of patients with racial and ethnic diversity. As
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reported by Taylor et al. in an early study of racial and ethnic
disparities in diabetes care, non-Hispanic black patients had a
25% lower odds ratio for achieving HbA1c levels of <8.0%
and 58% higher odds ratio of sustaining HbA1c levels at
>9.0%.83 An analysis of unpublished Medicare data revealed
that a notably higher percentage of non-Hispanic black
(>75%) and Hispanic (>75%) insulin-treated beneficiaries
are ineligible for CGM based on their current SMBG frequency. Importantly, although an early study by Groeneveld
et al. found that there were inconsistent differences between
non-Hispanic black and non-Hispanic white patients in their
openness to using innovative technology,84 a recent study of
300 young adult T1D patients found notably lower use of
CGM among non-Hispanic black (28%) and Hispanic (37%)
patients compared with non-Hispanic white (71%) patients.85
Many researchers add a qualifier at the end of their published study reports, explaining how additional studies are
needed to further understand their findings and/or support
their conclusions. For this report, no such qualifier is needed. Given the demonstrated clinical benefits and lower
rates of diabetes-related hospitalizations associated with
CGM use, limiting access to CGM technology achieves
neither cost-efficiencies nor clinical efficacies. We believe
our evidence-based recommendations for modifying current
eligibility criteria both streamline the administrative processes for documenting medical necessity, expand access to
CGM and improve the safety of our most vulnerable diabetes population.
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